Skip to main content

Archived Comments for: Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)

Back to article

  1. Homocysteine as a competitive inhibitor of ciprofibrate for PPAR alpha and gamma

    Melvin Hayden, Department of Family and Community Medicine University of Missouri

    29 July 2004

    Congratulations on an excellent study and publication. I really enjoyed this well written paper and viewing the results of this study.

    Homocysteine has been found to be a competitive inhibitor of PPAR alpha and gamma recently in our laboratory and may be playing an important role in your observations especially in those with BMI greater than 25 as compared to those with a BMI less than 25. I would suggest that the data might be changed by the addition of folic acid in these patients to lower the homocysteine and reexamine the results if possible.

    It would be exciting if you could examine the levels of homocysteine and see if there is any correlation to your exciting published results.


    M.R. Hayden, M.D.

    See paper and references:

    Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation

    Melvin R Hayden, Suresh C Tyagi

    Nutrition Journal 2004, 3:4 (10 May 2004)

    References: [71-74] (figure 5)

    We look forward to your reply and ideas regarding this comment. M.R. Hayden, MD

    Competing interests

    There are no competing interests